Biocept Signs Canada Distribution Deal with Teneovita Medical | GenomeWeb

NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Teneovita Medical under which the Vancouver-based provider will market and distribute Biocept's Target Selector liquid biopsy testing services to hospitals, individual oncology practices, and other cancer centers in Canada.

Additional terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.